查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371952

2030 年超免疫球蛋白市場預測：按類型、最終用戶和地區分類的全球分析

Hyperimmune Globulins Market Forecasts to 2030 - Global Analysis By Type (Hepatitis B Immunoglobulins, Rabies Immunoglobulins, Rho Immunoglobulins, Tetanus Immunoglobulins and Other Types), By End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球超免疫球蛋白市場規模為 20.1 億美元，預計 2030 年將達到 36.9 億美元。

超免疫球蛋白是從個體血漿中獲得的特殊抗體製劑，具有針對特定病原體或抗原的高濃度抗體。這些抗體是從罹患特定疾病或接種過疫苗的捐贈者那裡獲得的，從而導致免疫系統產生強大的抗體反應。然後對超免疫球蛋白進行加工、精製和濃縮，以含有高水平的特異性抗體。這些製劑用於被動免疫，提供特定感染疾病的即時定向免疫。

各種感染疾病的流行

感染疾病仍然是全球面臨的重大健康挑戰，對有針對性的有效治療方法的需求持續成長。超免疫球蛋白含有高濃度的抗體，可以對抗特定的病原體，有助於預防和治療此類疾病。從肝炎到狂犬病感染疾病的罹患率不斷增加，促使醫療保健系統投資於超免疫球蛋白產品。隨著世界面臨已知和新出現的感染疾病的威脅，市場佔有率不斷增加，對抗這些疾病的新治療方法不斷增加，對超免疫球蛋白的需求仍然強勁，預計感染疾病發展將進一步加強。

捐贈者數量有限

超免疫球蛋白來自對某些病原體具有特異性抗體的個體。尋找足夠數量的具有必要抗體的捐贈者是一個困難且集中資源的過程。這種限制使得難以擴大生產規模以滿足對患病球蛋白的需求，特別是對於低流行性疾病和新出現的感染疾病威脅。此外，確保合格捐助者的持續和永續供應對於維持產品品質和功效至關重要。由於這種限制，超免疫球蛋白市場需要創新方法，例如人工抗體的開發以及更有效的捐贈者招募和收集策略，以克服捐贈者可用性的限制。

醫療保健專業人員的意識不斷增強

隨著醫療保健專業人員越來越了解超免疫球蛋白對特定感染疾病和病理的治療效果，他們更有可能向患者推薦和給藥這些專門的免疫球蛋白製劑。意識的提高可以促進早期診斷和治療，從而改善患者的治療效果。此外，資訊的醫療保健專業人員可以為擴大超免疫球蛋白針對已發現和新出現的感染疾病的研發和臨床應用做出貢獻。這將促進製藥公司和醫療保健提供者之間的合作，最終促進超免疫球蛋白療法的成長和可及性，同時改善患者照護和公共衛生結果。

保存期限有限

超免疫球蛋白產品的保存期限通常相對較短，這可能會對儲存、運輸和分銷帶來物流挑戰。在整個供應鏈中維持所需的溫度和儲存條件可能非常複雜且成本高昂。這種限制可能會導致產品浪費和經濟損失，尤其是在指定期限內無法滿足需求的情況下。此外，有效的庫存管理對於防止過期和產品短缺也是必要的。減輕這項威脅需要儲存技術的創新、延長產品的保存期限和改進的分配系統，以確保超免疫球蛋白及時有效地到達患者手中。

COVID-19 的影響：

COVID-19 大流行加速了遠距醫療的採用，並增加了對家庭超免疫球蛋白的需求。隨著越來越多的人避開醫療機構，這些設備可以幫助人們在家中監測血壓並幫助管理慢性病。遠端健康諮詢和遠端監測已變得至關重要，數位和智慧型手機整合監測儀也普及越來越普遍。此次疫情凸顯了自我照護和早期發現的重要性，推動了這段時期血壓監測技術的創新和便利性。

醫院和診所預計將在預測期內成為最大的細分市場

醫院和診所在超免疫球蛋白市場中非常重要，它們是需要這些專門免疫球蛋白療法的患者的主要護理和給藥中心。這些醫療機構是超免疫球蛋白產品的分銷和使用的中心，也是某些感染疾病的診斷、治療和預防的中心。醫院和診所負責診斷需要超免疫球蛋白的疾病、實施治療和管理病患照護。這些醫院和診所也是提高人們對超免疫球蛋白益處的認知的重要倡導者，並且通常負責採購和儲存這些產品。超免疫球蛋白市場的成功和成長與醫院和診所在患者照護和公共衛生方面的參與和積極作用密切相關。

在預測期內，狂犬病免疫球蛋白領域預計將具有最高的年複合成長率

由於狂犬病預防意識的提高、某些地區狂犬病發病率的上升以及生產技術的改進，預計狂犬病免疫球蛋白領域在預測期內將出現顯著成長。各國政府和衛生保健組織已啟動狂犬病控制計畫來解決這個公共衛生問題。此外，正在進行的研究和開發旨在提高狂犬病免疫球蛋白的效率和價格。狂犬病免疫球蛋白在狂犬病防治中發揮的重要作用，保證了超免疫球蛋白市場將持續成長。

比例最高的地區：

北美超免疫球蛋白市場預計近年來將經歷強勁成長。這種快速成長是由於人們對被動免疫的認知增強，特別是在高危險群中。感染疾病罹患率的增加以及對快速起效的標靶免疫的需求正在推動需求。此外，醫療機構、研究機構和製藥公司之間的策略聯盟正在加速研發。北美憑藉其發達的醫療基礎設施、嚴格的法律規範和不斷成長的醫療支出，可能會繼續引領超免疫球蛋白市場的成長。

複合年複合成長率最高的地區：

預計北美在預測期內將出現良好的成長。超免疫球蛋白在亞太地區的醫療保健中發揮重要作用。這些專門的抗體製劑對於應對和預防這個多樣化和人口稠密地區流行的各種感染疾病至關重要。乙型肝炎、狂犬病和破傷風等疾病是主要的公共衛生問題。此外，亞太地區廣闊的區域形勢和人口多樣性凸顯了這些準備工作在保護公眾健康和減輕感染疾病影響方面的重要性，而該地區的醫療保健已成為這種情況下的一個重要因素。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球超免疫球蛋白市場：按類型

  • 乙型肝炎免疫球蛋白
  • 狂犬病免疫球蛋白
  • Rho(D) 免疫球蛋白
  • 破傷風免疫球蛋白
  • 其他類型

第6章 全球超免疫球蛋白市場：依最終用戶分類

  • 醫院和診所
  • 血庫和捐贈中心
  • 政府機關
  • 家庭保健
  • 製藥公司
  • 其他最終用戶

第7章 全球超免疫球蛋白市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第8章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第9章 公司簡介

  • ADMA Biologics
  • Biotest
  • China National Biotec Group Company Limited（CNBG）
  • CSL Behring
  • Emergent（Cangene）
  • Grifols
  • Hualan Bio
  • Kamada
  • Kedrion
  • Shanghai Raas Blood Products Co. Ltd
  • Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd.
Product Code: SMRC24009

According to Stratistics MRC, the Global Hyperimmune Globulins Market is accounted for $2.01 billion in 2023 and is expected to reach $3.69 billion by 2030 growing at a CAGR of 9% during the forecast period. Hyperimmune globulins are specialized preparations of antibodies that are derived from the blood plasma of individuals who have a high concentration of antibodies against a specific pathogen or antigen. These antibodies are collected from donors who have been exposed to or vaccinated against a particular disease, resulting in their immune system producing a robust antibody response. Hyperimmune globulins are then processed, purified, and concentrated to contain high levels of specific antibodies. These preparations are used for passive immunization, providing immediate and targeted immunity against particular infections.

Market Dynamics:

Driver:

The prevalence of various infectious diseases

The infectious diseases continuing to pose significant global health challenges, there is an ever-growing demand for targeted and effective therapies. Hyperimmune globulins, containing high concentrations of specific pathogen-fighting antibodies, are instrumental in preventing and treating such diseases. The increasing incidence of infectious diseases, ranging from hepatitis to rabies, prompts healthcare systems to invest in hyperimmune globulin products, as they offer critical support for patients, especially in cases where conventional treatments may be limited. As the world faces both known and emerging infectious threats, the demand for hyperimmune globulins is expected to remain robust, further bolstering their market presence and the development of new therapies to combat these diseases.

Restraint:

Limited availability of donors

Hyperimmune globulins are derived from individuals who possess specific antibodies against a particular pathogen. Finding an adequate number of donors with the necessary antibodies can be a challenging and resource-intensive process. This limitation can result in difficulties in scaling up production to meet the demand for hyperimmune globulins, particularly for diseases with a low prevalence or for emerging infectious threats. Moreover, ensuring a consistent and sustainable supply of qualified donors is essential for maintaining product quality and efficacy. This constraint necessitates innovative approaches, such as the development of artificial antibodies or more efficient donor recruitment and collection strategies, to overcome the limited availability of donors in the hyperimmune globulins market.

Opportunity:

Growing awareness among healthcare professionals

As healthcare providers become more informed about the therapeutic benefits of hyperimmune globulins in addressing specific infectious diseases and conditions, they are more likely to recommend and administer these specialized immunoglobulin products to their patients. Enhanced awareness can lead to earlier diagnosis and treatment, resulting in better patient outcomes. Additionally, informed healthcare professionals can contribute to increased research, development, and clinical utilization of hyperimmune globulins for both existing and emerging infectious diseases. This can foster collaboration between pharmaceutical companies and healthcare practitioners, ultimately driving the growth and accessibility of hyperimmune globulin therapies, while improving patient care and public health outcomes.

Threat:

Limited shelf life

Hyperimmune globulin products typically have a relatively short shelf life, which can lead to logistical challenges in terms of storage, transportation, and distribution. Maintaining the required temperature and storage conditions throughout the supply chain can be complex and costly. This constraint can result in product wastage, especially if the demand is not met within the specified timeframe, leading to financial losses. It also necessitates efficient inventory management to prevent expiration and product shortages. To mitigate this threat, there is a need for innovations in storage and preservation techniques, extended shelf life products, and improved distribution systems to ensure that hyperimmune globulins reach patients in a timely and effective manner.

COVID-19 Impact:

The COVID-19 pandemic has accelerated the adoption of remote healthcare, increasing the demand for home Hyperimmune Globulins. With more people avoiding healthcare facilities, these devices allow individuals to monitor their blood pressure from home, aiding in the management of chronic conditions. Telehealth consultations and remote monitoring have become essential, making digital and smartphone-integrated monitors more popular. The pandemic has underscored the importance of self-care and early detection, driving innovation and convenience in blood pressure monitoring technology during this period.

The hospitals & clinics segment is expected to be the largest during the forecast period

Hospitals and clinics are significant in the hyperimmune globulins market as primary points of care and administration for patients in need of these specialized immunoglobulin therapies. These healthcare facilities are central in the distribution and utilization of hyperimmune globulin products, serving as hubs for diagnosis, treatment, and preventive measures against specific infectious diseases. Hospitals and clinics are responsible for diagnosing conditions that require hyperimmune globulins, administering treatments, and managing patient care. They also serve as key advocates in raising awareness about the benefits of hyperimmune globulins and, in many cases, are responsible for procuring and stocking these products. The success and growth of the hyperimmune globulins market are closely tied to the engagement and proactive role of hospitals and clinics in patient care and public health.

The rabies immunoglobulins segment is expected to have the highest CAGR during the forecast period

The rabies immunoglobulins segment is expected to witness significant growth over the forecast period driven by increasing awareness of rabies prevention, a rising incidence of rabies in certain regions, and improved production techniques. Governments and healthcare organizations have initiated rabies control programs to address this public health concern. Moreover, ongoing research and development efforts aim to enhance the efficiency and affordability of rabies immunoglobulins. The critical role that rabies immunoglobulins play in preventing and treating rabies ensures their continued growth within the broader hyperimmune globulins market.

Region with largest share:

The market for Hyperimmune Globulins in North America is expected to witness robust growth in recent years. This surge can be attributed to rising awareness about passive immunization, especially in high-risk populations. Increasing incidence of infectious diseases and the need for immediate, targeted immunity have driven demand. Additionally, strategic collaborations between healthcare institutions, research organizations, and pharmaceutical companies have accelerated research and development efforts. With a well-established healthcare infrastructure, stringent regulatory framework, and growing healthcare expenditure, North America is poised to continue leading in hyperimmune globulins market growth.

Region with highest CAGR:

During the forecast period, North America is anticipated to witness lucrative growth. Hyperimmune globulins play a critical role in healthcare throughout the Asia-Pacific region. These specialized antibody preparations are vital for addressing and preventing a range of infectious diseases prevalent in this diverse and populous area. Diseases like hepatitis B, rabies, and tetanus are significant public health concerns. Moreover, Asia-Pacific's vast geographic and demographic diversity underscores the importance of these preparations in safeguarding public health and mitigating the impact of infectious diseases, making them an essential component of the healthcare landscape in the region.

Key players in the market:

Some of the key players in Hyperimmune Globulins market include: ADMA Biologics, Biotest, China National Biotec Group Company Limited (CNBG), CSL Behring, Emergent (Cangene), Grifols, Hualan Bio, Kamada, Kedrion, Shanghai Raas Blood Products Co. Ltd and Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd.

Key Developments:

In July 2023, Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, has announced that China's National Institutes for Food and Drug Control (NIFDC) has approved BPL's human Albumin product for release to the Chinese market. In 2022, Kedrion joined forces with BPL, a UK-based company with over 60 years of experience in the supply of high-quality plasma-derived medicines for the treatment of rare diseases.

In March 2023, Grifols entered into a collaboration and licensing agreement with Selagine to develop immunoglobulin (Ig) eye drops to treat dry eye disease. Under the terms of the agreement, Grifols will have worldwide exclusive commercial rights to Selagine's treatment once it receives the regulatory authorization, expected in early 2029.

In January 2022, LFB and Kedrion signed an industrial cooperation agreement to supply immunoglobulins to meet patient demand in France. Two leading European pharmaceutical companies, LFB and Kedrion, are joining forces in an industrial cooperation agreement to increase the availability of immunoglobulin, a plasma-derived medicine, for patients in France.

Types Covered:

  • Hepatitis B Immunoglobulins
  • Rabies Immunoglobulins
  • Rho(D) Immunoglobulins
  • Tetanus Immunoglobulins
  • Other Types

End Users Covered:

  • Hospitals & Clinics
  • Blood Banks and Donation Centers
  • Government Institutions
  • Home Healthcare
  • Pharmaceutical Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hyperimmune Globulins Market, By Type

  • 5.1 Introduction
  • 5.2 Hepatitis B Immunoglobulins
  • 5.3 Rabies Immunoglobulins
  • 5.4 Rho(D) Immunoglobulins
  • 5.5 Tetanus Immunoglobulins
  • 5.6 Other Types

6 Global Hyperimmune Globulins Market, By End User

  • 6.1 Introduction
  • 6.2 Hospitals & Clinics
  • 6.3 Blood Banks and Donation Centers
  • 6.4 Government Institutions
  • 6.5 Home Healthcare
  • 6.6 Pharmaceutical Companies
  • 6.7 Other End Users

7 Global Hyperimmune Globulins Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 ADMA Biologics
  • 9.2 Biotest
  • 9.3 China National Biotec Group Company Limited (CNBG)
  • 9.4 CSL Behring
  • 9.5 Emergent (Cangene)
  • 9.6 Grifols
  • 9.7 Hualan Bio
  • 9.8 Kamada
  • 9.9 Kedrion
  • 9.10 Shanghai Raas Blood Products Co. Ltd
  • 9.11 Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd.

List of Tables

  • Table 1 Global Hyperimmune Globulins Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
  • Table 4 Global Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
  • Table 5 Global Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
  • Table 6 Global Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
  • Table 7 Global Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 8 Global Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
  • Table 9 Global Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 10 Global Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
  • Table 11 Global Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
  • Table 12 Global Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 13 Global Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 14 Global Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 15 North America Hyperimmune Globulins Market Outlook, By Country (2021-2030) ($MN)
  • Table 16 North America Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
  • Table 17 North America Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
  • Table 18 North America Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
  • Table 19 North America Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
  • Table 20 North America Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
  • Table 21 North America Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 22 North America Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
  • Table 23 North America Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 24 North America Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
  • Table 25 North America Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
  • Table 26 North America Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 27 North America Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 28 North America Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 29 Europe Hyperimmune Globulins Market Outlook, By Country (2021-2030) ($MN)
  • Table 30 Europe Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
  • Table 31 Europe Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
  • Table 32 Europe Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
  • Table 33 Europe Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
  • Table 34 Europe Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
  • Table 35 Europe Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 36 Europe Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
  • Table 37 Europe Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 38 Europe Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
  • Table 39 Europe Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
  • Table 40 Europe Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 41 Europe Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 42 Europe Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 43 Asia Pacific Hyperimmune Globulins Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Asia Pacific Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
  • Table 45 Asia Pacific Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
  • Table 46 Asia Pacific Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
  • Table 47 Asia Pacific Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
  • Table 48 Asia Pacific Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
  • Table 49 Asia Pacific Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 50 Asia Pacific Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
  • Table 51 Asia Pacific Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 52 Asia Pacific Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
  • Table 53 Asia Pacific Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
  • Table 54 Asia Pacific Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 55 Asia Pacific Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 56 Asia Pacific Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 57 South America Hyperimmune Globulins Market Outlook, By Country (2021-2030) ($MN)
  • Table 58 South America Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
  • Table 59 South America Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
  • Table 60 South America Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
  • Table 61 South America Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
  • Table 62 South America Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
  • Table 63 South America Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 64 South America Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
  • Table 65 South America Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 66 South America Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
  • Table 67 South America Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
  • Table 68 South America Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 69 South America Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 70 South America Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 71 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Country (2021-2030) ($MN)
  • Table 72 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
  • Table 73 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
  • Table 74 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
  • Table 75 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
  • Table 76 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
  • Table 77 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 78 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
  • Table 79 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 80 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
  • Table 81 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
  • Table 82 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 83 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 84 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)